STOCK TITAN

Actinium Pharmaceuticals to Present Business Update at Trump Mar-A-Lago Club Today

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Positive)
Tags
conferences

Actinium Pharmaceuticals (NYSE: ATNM) announced a business update presentation at Trump Mar-a-Lago Club, following their March 25th Investor KOL Event. The company highlighted three key clinical programs targeting multi-billion-dollar markets:

1. Actimab-A for myeloid malignancies and solid tumors:

  • Phase 2/3 trial in combination with CLAG-M for AML
  • Clinical trials for solid tumors with PD-1 inhibitors

2. Iomab-ACT for cell & gene therapy conditioning:

  • Commercial CAR-T trial data from UT Southwestern
  • Sickle cell disease trial data from Columbia University

3. Infrastructure Development:

  • Manufacturing facility build-out starting next quarter
  • Proprietary Actinium-225 cyclotron technology development

The company reports a strong balance sheet with runway into mid-2027, with multiple clinical milestones expected in 2025.

Actinium Pharmaceuticals (NYSE: ATNM) ha annunciato una presentazione di aggiornamento aziendale presso il Trump Mar-a-Lago Club, a seguito del loro evento per investitori KOL del 25 marzo. L'azienda ha messo in evidenza tre importanti programmi clinici che mirano a mercati da miliardi di dollari:

1. Actimab-A per le neoplasie mieloidi e i tumori solidi:

  • Studio clinico di fase 2/3 pianificato con CLAG-M per AML in recidiva/rifrangente
  • Nuovi trial in AML di prima linea e tumori solidi, inclusi il cancro testa-collo e il cancro polmonare non a piccole cellule

2. Iomab-ACT per la condizionamento della terapia cellulare e genica:

  • Trial in corso presso UT Southwestern per CAR-T e alla Columbia University per la malattia falciforme

3. Sviluppo delle infrastrutture:

  • Costruzione dell'impianto di produzione in partenza dal prossimo trimestre
  • Sviluppo della tecnologia ciclotrone proprietaria Actinium-225

L'azienda riporta un forte bilancio con liquidità fino a metà 2027, con molteplici letture di dati clinici attese nel 2025.

Actinium Pharmaceuticals (NYSE: ATNM) anunció una presentación de actualización empresarial en el Club Mar-a-Lago de Trump, tras su evento para inversores KOL del 25 de marzo. La compañía destacó tres importantes programas clínicos que apuntan a mercados de miles de millones de dólares:

1. Actimab-A para malignidades mieloides y tumores sólidos:

  • Ensayo clínico de fase 2/3 planificado con CLAG-M para AML en recaída/refractaria
  • Nuevos ensayos en AML de primera línea y tumores sólidos, incluyendo cáncer de cabeza y cuello y cáncer de pulmón no microcítico

2. Iomab-ACT para el acondicionamiento de terapia celular y génica:

  • Ensayos en curso en UT Southwestern para CAR-T y en la Universidad de Columbia para la enfermedad de células falciformes

3. Desarrollo de Infraestructura:

  • Construcción de la instalación de fabricación comenzando el próximo trimestre
  • Desarrollo de la tecnología de ciclotrón propietaria Actinium-225

La compañía informa de un sólido balance con recursos hasta mediados de 2027, con múltiples lecturas de datos clínicos esperadas para 2025.

액티늄 제약 (NYSE: ATNM)은 3월 25일 투자자 KOL 행사 이후 트럼프 마라라고 클럽에서 비즈니스 업데이트 프레젠테이션을 발표했습니다. 회사는 수십억 달러 규모의 시장을 겨냥한 세 가지 주요 임상 프로그램을 강조했습니다:

1. 액티맙-A는 골수 악성 종양 및 고형 종양:

  • 재발/불응성 AML을 위한 CLAG-M과 함께 계획된 2/3상 시험
  • 전선 AML 및 고형 종양에 대한 새로운 시험, 머리와 목의 암 및 비소세포 폐암 포함

2. 아이오맙-ACT는 세포 및 유전자 치료 조건화:

  • CAR-T를 위한 UT Southwestern 및 겸상 적혈구 질환을 위한 컬럼비아 대학교에서 진행 중인 시험

3. 인프라 개발:

  • 다음 분기에 제조 시설 구축 시작
  • 독점적인 액티늄-225 사이클로트론 기술 개발

회사는 2027년 중반까지 자금 여유가 있는 강력한 재무 상태를 보고하며, 2025년에는 여러 임상 데이터 결과가 예상됩니다.

Actinium Pharmaceuticals (NYSE: ATNM) a annoncé une présentation de mise à jour commerciale au Club Mar-a-Lago de Trump, suite à leur événement pour investisseurs KOL du 25 mars. L'entreprise a mis en avant trois programmes cliniques majeurs ciblant des marchés de plusieurs milliards de dollars :

1. Actimab-A pour les maladies malignes myéloïdes et les tumeurs solides :

  • Essai de phase 2/3 prévu avec CLAG-M pour l'AML en rechute/réfractaire
  • Nouveaux essais dans l'AML de première ligne et les tumeurs solides, y compris le cancer de la tête et du cou et le cancer du poumon non à petites cellules

2. Iomab-ACT pour le conditionnement de thérapies cellulaires et géniques :

  • Essais en cours à l'UT Southwestern pour CAR-T et à l'Université de Columbia pour la drépanocytose

3. Développement d'infrastructure :

  • Construction de l'installation de fabrication à partir du trimestre prochain
  • Développement de la technologie de cyclotron propriétaire Actinium-225

L'entreprise rapporte un bilan solide avec des ressources financières jusqu'à mi-2027, avec plusieurs résultats de données cliniques attendus en 2025.

Actinium Pharmaceuticals (NYSE: ATNM) gab eine Unternehmenspräsentation im Trump Mar-a-Lago Club bekannt, nach ihrer Investoren KOL-Veranstaltung am 25. März. Das Unternehmen hob drei wichtige klinische Programme hervor, die auf Märkte im Wert von mehreren Milliarden Dollar abzielen:

1. Actimab-A für myeloische Malignome und solide Tumoren:

  • Geplante Phase 2/3-Studie mit CLAG-M für rezidivierende/refraktäre AML
  • Neue Studien in der Erstlinientherapie bei AML und soliden Tumoren einschließlich Kopf-Hals-Krebs und nicht-kleinzelligem Lungenkrebs

2. Iomab-ACT für die Konditionierung von Zell- und Gentherapien:

  • Laufende Studien an der UT Southwestern für CAR-T und an der Columbia University für Sichelzellenanämie

3. Infrastrukturentwicklung:

  • Der Bau der Produktionsstätte beginnt im nächsten Quartal
  • Entwicklung der proprietären Actinium-225 Cyclotron-Technologie

Das Unternehmen berichtet von einer soliden Bilanz mit finanziellen Mitteln bis Mitte 2027, wobei mehrere klinische Datenveröffentlichungen für 2025 erwartet werden.

Positive
  • None.
Negative
  • None.

- Company to highlight recent significant progress made with its Actimab-A and Iomab-ACT clinical programs, leading-edge R&D and radiopharmaceutical manufacturing infrastructure

- Revitalized clinical programs focused on 3 separate multi-billion-dollar market opportunities in
myeloid malignancies, solid tumors and cell & gene therapy conditioning with clinical data
expected in 2025 supporting each addressable market

- Presentation follows Investor KOL Event and Company Update on March 25th

NEW YORK, March 26, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, announced it will be presenting a business update today at Trump Mar-a-Lago Club, Florida. This presentation follows an Investor KOL Call and Company Update hosted by Actinium on Tuesday, March 25th highlighting its revitalized clinical programs and expanded market opportunities. Actinium's Investor KOL Call and Company Update can be accessed for replay here.  

Sandesh Seth, Actinium's Chairman and CEO, said, "We are honored to have this opportunity to present Actinium Pharmaceuticals and highlight the significant progress we have made in the last several months at the Mar-a-Lago Club. We have great enthusiasm for our revamped clinical programs and expect to achieve significant milestones in 2025. If successful, we will have the opportunity to address multiple potential blockbuster market opportunities with Actimab-A in myeloid malignancies and solid tumors and with Iomab-ACT for cell and gene therapy conditioning."

Actinium has outlined its expanded market opportunities and expected 2025 milestones for each of its clinical programs as well as its R&D and radiopharmaceutical manufacturing capabilities as follows:

Actimab-A as a mutation agnostic, backbone therapy for myeloid malignancies including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) across multiple treatment settings

  • Initiate Phase 2/3 trial in combination with CLAG-M in relapsed or refractory AML and seek potential partners or collaborators
  • Generate initial clinical data in frontline AML in first trial under CRADA with NCI
  • Initiate additional clinical trials in myeloid malignancies

Actimab-A as a pan solid tumor therapy in combination with PD-1 inhibitors including KEYTRUDA and OPDIVO by depleting myeloid derived suppressor cells (MDSCs)

  • Generate clinical proof of concept data in head and neck squamous cell carcinoma and non-small cell lung cancer
  • Explore additional solid tumor indications for future trials

Iomab-ACT as a universal targeted conditioning agent to increase patients access to cell & gene therapies and improve patient outcomes

  • Present initial data from commercial CAR-T trial at University of Texas Southwestern
  • Generate clinical data in first non-malignant indication from sickle cell disease allogeneic stem cell transplant trial at Columbia University

Pipeline Expansion Leveraging Targeted Radiotherapy R&D Capabilities

  • Present abstract at AACR highlighting Actinium-225 targeted radiotherapy for novel radiotherapy cancer target

Establish In-house Radiopharmaceutical Manufacturing & Production

  • Advance build-out of manufacturing facility
  • Explore strategic partnerships leveraging proprietary Actinium-225 cyclotron manufacturing technology

Mr. Seth continued, "In addition to the multitude of milestones that lie ahead for our clinical programs, we are excited to highlight our expanding capabilities. As a pioneer in targeted radiotherapy, we are leveraging our robust know-how and intellectual property to develop new pipeline programs to address indications with high unmet needs. In addition, we are investing in our infrastructure and are thrilled to be moving ahead with the build-out of our manufacturing facility starting next quarter in anticipation of future clinical success. Finally, we look forward to fully leveraging our proprietary Actinium-225 cyclotron manufacturing technology to meet our projected demand given our expanding Actinium-225 programs as well as facilitate strategic partnerships. With our strong balance sheet providing runway into mid-2027, our team is focused and committed on execution and value creation."

About Actinium Pharmaceuticals, Inc.

Actinium is a pioneer in the development of targeted radiotherapies intended to meaningfully improve patient outcomes. Actinium is advancing its lead product candidate Actimab-A, a CD33 targeting therapeutic, as potential backbone therapy in acute myeloid leukemia (AML) and other myeloid malignancies leveraging the mutation agnostic alpha-emitter radioisotope payload Actinium-225 (Ac-225). Actimab-A has demonstrated potential activity in relapsed and refractory acute myeloid leukemia (r/r AML) patients in combination with the chemotherapy CLAG-M including high rates of Complete Remissions (CR) and measurable residual disease (MRD) negativity leading to improved survival outcomes and is being advanced to a pivotal Phase 2/3 trial. In addition, Actinium is engaged with the National Cancer Institute (NCI) under the Cooperative Research and Development Agreement (CRADA) for development of Actimab-A in AML and other myeloid malignancies. The first clinical trial under the CRADA will evaluate the triplet combination comprised of Actimab-A, Venetoclax (Abbvie/Roche) an oral Bcl-2 inhibitor and ASTX-727 (Taiho Oncology, an Otsuka holdings company) a novel oral hypomethylating agent (HMA) in frontline acute myeloid leukemia (AML) patients. Additionally, Actinium is developing Actimab-A as a potential pan tumor therapy in combination with PD-1 checkpoint inhibitors including KEYTRUDA® and OPDIVO® by depleting myeloid derived suppressor cells (MDSCs), which represents a potential multi-billion-dollar addressable market. Iomab-ACT, Actinium's next generation conditioning candidate, is being developed with the goal of improving patient access and outcomes for potentially curative cell and gene therapies. Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with r/r AML, which Actinium is seeking a potential strategic partner for  the U.S. In addition, the company's R&D efforts are primarily focused on advancing several preclinical programs for solid tumor indications. Actinium holds 230 patents and patent applications including several patents related to the manufacture of the isotope Ac-225 in a cyclotron.

For more information, please visit: https://www.actiniumpharma.com/

Forward-Looking Statements

This press release may contain projections or other "forward-looking statements" within the meaning of the "safe-harbor" provisions of the private securities litigation reform act of 1995 regarding future events or the future financial performance of the Company which the Company undertakes no obligation to update. These statements are based on management's current expectations and are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with preliminary study results varying from final results, estimates of potential markets for drugs under development, clinical trials, actions by the FDA and other governmental agencies, regulatory clearances, responses to regulatory matters, the market demand for and acceptance of Actinium's products and services, performance of clinical research organizations and other risks detailed from time to time in Actinium's filings with the Securities and Exchange Commission (the "SEC"), including without limitation its most recent annual report on form 10-K, subsequent quarterly reports on Forms 10-Q and Forms 8-K, each as amended and supplemented from time to time.

Investors:
investorrelations@actiniumpharma.com 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/actinium-pharmaceuticals-to-present-business-update-at-trump-mar-a-lago-club-today-302411734.html

SOURCE Actinium Pharmaceuticals, Inc.

FAQ

What are the key clinical trials Actinium Pharmaceuticals (ATNM) is conducting in 2025?

ATNM is conducting Phase 2/3 trials for Actimab-A in AML, solid tumor trials with PD-1 inhibitors, and Iomab-ACT trials for CAR-T therapy and sickle cell disease.

How long will Actinium Pharmaceuticals' (ATNM) current financial runway last?

ATNM reports having a strong balance sheet providing runway into mid-2027.

What are the three main market opportunities ATNM is targeting with its clinical programs?

ATNM is targeting myeloid malignancies, solid tumors, and cell & gene therapy conditioning markets.

What infrastructure developments is ATNM planning for 2025?

ATNM plans to build out a manufacturing facility starting next quarter and develop proprietary Actinium-225 cyclotron manufacturing technology.

What are the planned applications for ATNM's Actimab-A therapy?

Actimab-A is being developed for myeloid malignancies (AML and MDS) and as a pan solid tumor therapy in combination with PD-1 inhibitors.
Actinium Pharmac

NYSE:ATNM

ATNM Rankings

ATNM Latest News

ATNM Stock Data

56.25M
30.64M
1.79%
29.67%
7.2%
Biotechnology
Pharmaceutical Preparations
Link
United States
NEW YORK